[HTML][HTML] Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in …

…, L Ceriani, E Garcia, N Kreplak, M Pifano… - …, 2021 - thelancet.com
Background A first-dose of various vaccines provides acceptable protection against infections
by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant …

[PDF][PDF] Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose

…, N Kreplak, M Yanovsky, J Geffner, M Pifano… - Cell Reports …, 2021 - cell.com
Massive vaccination offers great promise for halting the global COVID-19 pandemic. However,
the limited supply and uneven vaccine distribution create an urgent need to optimize …

[PDF][PDF] Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273

…, G Docena, CH Laino, N Kreplak, M Pifano… - Cell Reports …, 2022 - cell.com
Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational
strategy to rapidly increase vaccination coverage in many regions of the world. Although …

Longitudinal study after Sputnik V vaccination shows durable SARS-CoV-2 neutralizing antibodies and reduced viral variant escape to neutralization over time

…, N Kreplak, M Yanovsky, S Whelan, J Geffner, M Pifano… - Mbio, 2022 - Am Soc Microbiol
Recent studies have shown a temporal increase in the neutralizing antibody potency and
breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent …

[HTML][HTML] The novel desmopressin analogue [V4Q5] dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast …

J Garona, M Pifano, UD Orlando… - International …, 2015 - spandidos-publications.com
Desmopressin (dDAVP) is a safe haemostatic agent with previously reported antitumour activity.
It acts as a selective agonist for the V2 vasopressin membrane receptor (V2r) present on …

Antibody durability at 1 year after Sputnik V vaccination

L Sanchez, SO Rouco, M Pifano, DS Ojeda… - The Lancet Infectious …, 2022 - thelancet.com
Antibody waning against SARS-CoV-2 over time after vaccination, together with the emergence
of new viral variants, pose great challenges for ending the pandemic. To our knowledge, …

[HTML][HTML] A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients

…, D Di Leo, E Spitzer, GN Ciccia, J Garona, M Pifano… - Springerplus, 2015 - Springer
Desmopressin (dDAVP) is a well-known peptide analog of the antidiuretic hormone
vasopressin, used to prevent excessive bleeding during surgical procedures. dDAVP increases …

[HTML][HTML] Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model

GV Ripoll, J Garona, M Pifano, HG Farina… - Breast cancer research …, 2013 - Springer
Desmopressin (DDAVP), a synthetic peptide analog of vasopressin, is a safe antidiuretic
and hemostatic compound that acts as a selective agonist for the vasopressin V2 membrane …

Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells

…, GA Cardama, MJ Comin, VI Segatori, M Pifano… - Cellular signalling, 2017 - Elsevier
Tamoxifen is a standard endocrine therapy for estrogen receptor positive breast cancer
patients. Despite its success, development of resistance mechanisms is still a serious clinical …

[HTML][HTML] Preclinical efficacy of [V4Q5] dDAVP, a second generation vasopressin analog, on metastatic spread and tumor-associated angiogenesis in colorectal cancer

J Garona, NT Sobol, M Pifano, VI Segatori… - Cancer Research and …, 2019 - ncbi.nlm.nih.gov
Purpose Control of metastatic spread of colorectal cancer (CRC) remains as a major
therapeutic challenge.[V4 Q5] dDAVP is a vasopressin peptide analog with previously reported …